LANCET CHILD & ADOLESCENT HEALTH, cilt.2, sa.7, ss.495-504, 2018 (SCI-Expanded)
Background Epilepsy occurs in 70-90% of patients with tuberous sclerosis complex. We aimed to assess the efficacy and safety of adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex in paediatric patients enrolled in the EXIST-3 trial, a double-blind, placebo-controlled, randomised, phase 3 study.